Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
DNDenali Therapeutics Inc. logo

Denali Therapeutics Inc. (DNLI)

NASDAQ Global Select · Currency in USD
$18.41 ▼ -0.25 (-1.34%)
At close: Oct 23, 4:00 PM ET. Market closed.
$18.49 ▲ +0.08 (+0.43%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$18.66
Open
$18.49
Day's Range
$18.00 – $18.50
52 Week Range
$13.75 – $27.30
Volume
1,005,556
Avg. Volume
1,697,341
Market Cap
$2.94B
Beta (5Y Monthly)
1.02
PE Ratio (TTM)
--
EPS (TTM)
-$2.73
Earnings Date
Nov 3, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$33.67

Profile: Denali Therapeutics Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
503
CEO
Ryan J. Watts

Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease.

Earnings

Next report: Tue, Nov 3, 2026
EPS estimate -$0.32 · Revenue est. $12.22M
DateEst.Actual
Aug 6, 2026-$0.51-$0.68Miss
May 7, 2026-$0.73-$0.69Beat
Feb 26, 2026-$0.75-$0.73Beat
Nov 6, 2025-$0.76-$0.74Beat
Aug 11, 2025-$0.74-$0.72Beat
May 6, 2025-$0.71-$0.78Miss

Analyst view

Consensus price target
$33.67 ▲ +82.9%
Range $26.00 – $41.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on DNLI and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.